Étiquette : CB1 recepteur

Endocannabinoid-Mediated Control of Synaptic Transmission, Masanobu KANO et al., 2009

Endocannabinoid-Mediated Control of Synaptic Transmission Masanobu KANO, Takako OHNO-SHOSAKU, Yuki HASHIMOTODANI, Motokazu UCHIGASHIMA, and Masahiko WATANABE Physiological Reviews, 2009, 89, 1, 309-380. https://doi.org/10.1152/physrev.00019.2008 I. Introduction 310 II. Cannabinoid Receptors 311 A. CB1 receptor 311 B. CB2 receptor 315 C. “CB3” receptor 315 D. TRPV1 receptor 317 E. GPR55 receptor 317 III. CB1 Receptor Signaling 317 A. Intracellular signaling pathways 317 B. Suppression of transmitter release 318 C. Morphological changes 318 IV. Biochemistry of Endocannabinoids 318 A. Endocannabinoids 318 B. Biosynthesis of anandamide 319 C. Biosynthesis of 2-AG 320 D. Degradation of endocannabinoids 321 E. Endocannabinoid transport 321 F. Lipid raft 322 V. Endocannabinoid-Mediated Short-Term Depression 322 A. Endocannabinoid as a retrograde messenger 322 B. eCB-STD in various brain regions 324 C. Mechanisms of ecb-std 334 VI. [...]

Lire la suite

Medicinal Use of Synthetic Cannabinoids—a Mini Review , P. Muralidhar Reddy et al., 2019

Medicinal Use of Synthetic Cannabinoids—a Mini Review P. Muralidhar Reddy, Nancy Maurya & Bharath Kumar Velmurugan Current Pharmacology Reports, 2019 https://doi.org/10.1007/s40495-018-0165-y   Abstract Purpose of Review : This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review. Recent Findings Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than [...]

Lire la suite

REVIEW : Cannabidiol – Recent Advances, Raphael Mechoulam, 2007

REVIEW : Cannabidiol – Recent Advances Raphael Mechoulam, Maximilian Petersa, Eric Murillo-Rodriguez and Lumïr O. Hanus Chemistry and Biodiversity, 2007, 4, 1678-1692.   The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity. Contents 1. Introduction 2. Mechanisms of Cannabidiol Action 2.1. Cannabidiol: an [...]

Lire la suite

Les Phyto-cannabinoïdes Non-psychotropes : Les nouvelles Opportunités d’une plante ancienne, Angelo A. Izzo, Raphael Mechoulam et al., 2009

Les Phyto-cannabinoïdes Non-psychotropes* : Les nouvelles Opportunités d'une plante ancienne.(*NdT : non-stupéfiants) Angelo A. Izzo, Francesca Borrelli, Raffaele Capasso, Vincenzo Di Marzo and Raphael Mechoulam Trends in Pharmacological Sciences - CELL Press, 2009, 30, 10, 515-27. doi: 10.1016/j.tips.2009.07.006.   Le Δ9-tetrahydrocannabinol (Δ9THC) se lie aux récepteurs endocannabinoïdes (CB1 et CB2) qui sont activés par les cannabinoïdes endogènes (endocannabinoïdes) et qui sont impliqués dans une large gamme de processus physiopathologiques (exemple: modulation de la libération de neurotransmetteurs, régulation de la perception de la douleur, régulation des fonctions cardiovasculaires, gastro-intestinales et hépatiques). Les effets psychotropes bien connus du Δ9THC qui sont véhiculés par l'activation des récepteurs CB1 [...]

Lire la suite

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment, Ester Aso et al., 2019

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment Ester Aso, Víctor Fernández-Dueñas, Marc López-Cano, Jaume Taura, Masahiko Watanabe, Isidre Ferrer, Rafael Luján, Francisco Ciruela, Ester Aso Molecular Neurobiology, First Online: 04 January 2019, pp 1-10. C : Springer Nature Switzerland AG Abstract : At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can counteract the undesirable effects of the psychoactive cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) that hinder clinical development of cannabis-based therapies. Despite this attention, the mechanisms of CBD action and its interaction with Δ9-THC are still not completely elucidated. Here, by combining in vivo [...]

Lire la suite

The Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury, Lital MAJID et al., 2018

The Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury Lital MAJID, Sami HEYMAN, Merav ELGALI ... Esther SHOHAMI et al. Journal of Neurotrauma, Nov 2018, 36, 1-11 DOI: 10.1089/neu.2018.6063   Abstract : Cannabis is one of the most widely used plant drugs in the world today. In spite of the large number of scientific reports on medical marijuana, there still exists much controversy surrounding its use and the potential for abuse due to the undesirable psychotropic effects. However, recent developments in medicinal chemistry of novel non-psychoactive synthetic cannabinoids have indicated that it is possible to separate some of the therapeutic effects [...]

Lire la suite

The endocannabinoid system as a target for novel anxiolytic drugs, S. Patel et al., 2017

The endocannabinoid system as a target for novel anxiolytic drugs S. Patel, M.N. Hill, J.F. Cheer, C.T. Wotjak, A. Holmes, Neuroscience and Biobehavioral Reviews, 2017, 76, 56-66. https://doi.org/10.1016/j.neubiorev.2016.12.033 Abstract The endocannabinoid (eCB) system has attracted attention for its role in various behavioral and brain functions, and as a therapeutic target in neuropsychiatric disease states, including anxiety disorders and other conditions resulting from dysfunctional responses to stress. In this mini-review, we highlight components of the eCB system that offer potential ‘druggable’ targets for new anxiolytic medications, emphasizing some of the less well-discussed options. We discuss how selectively amplifying eCBs recruitment by interfering with eCB-degradation, via fatty [...]

Lire la suite